Perioperative Management of Patients Receiving Immune Checkpoint Inhibitors
Journal of Onco-Anaesthesiology and Perioperative Medicine · 2026-05 · 3 (2) · 142-148
DOI: 10.4103/joapm.joapm_79_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Onco-Anaesthesiology and Perioperative Medicine, online erschienen am 01.05.2026. Verfasst von Pratishtha Yadav und 2 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Anti-cancer treatment is a rapidly evolving field, with new modalities emerging daily for treating cancer. Immunotherapy is a new group of drugs that has revolutionised cancer treatment. Immunotherapy drugs can manipulate the immune system to kill cancer cells. Immune checkpoint inhibitors (ICIs) are a class of immunotherapy drugs that block the naturally occurring checkpoints of the immune system, thereby facilitating the killing of cancer cells by the host immune system. ICI is indicated in a wide range of malignancies and is associated with several adverse events. In this narrative review, we aim to discuss specific peri-operative considerations for patients treated with ICI.
Zitieren
APA
Yadav, P., Goswami, J., & Garg, R. (2026). Perioperative Management of Patients Receiving Immune Checkpoint Inhibitors. Journal of Onco-Anaesthesiology and Perioperative Medicine, 3(2), 142-148. https://doi.org/10.4103/joapm.joapm_79_25
Vancouver
Yadav P, Goswami J, Garg R. Perioperative Management of Patients Receiving Immune Checkpoint Inhibitors. Journal of Onco-Anaesthesiology and Perioperative Medicine. 2026;3(2):142-148. doi:10.4103/joapm.joapm_79_25
BibTeX
@article{Yadav2026,
author = {Yadav, Pratishtha and Goswami, Jyotsana and Garg, Rakesh},
title = {Perioperative Management of Patients Receiving Immune Checkpoint Inhibitors},
journal = {Journal of Onco-Anaesthesiology and Perioperative Medicine},
year = {2026},
volume = {3},
number = {2},
pages = {142--148},
doi = {10.4103/joapm.joapm_79_25}
}
EUVIMED